The most eye-catching executive filing from early September comes from Cybin, the psychedelic medicine company. Two directors — Eric So and Paul Glavine — filed purchases totaling over $2.3M combined, filed on September 8. Both bought shares at market price on September 3–4. These were discretionary buys with no 10b5-1 plan attached. That's a strong signal. Cybin carries a market cap of just over $1B.
At Warner Bros. Discovery, director Kenneth Lowe filed a $5.7M sale on September 4. The trade occurred September 3. No further detail on plan status was available, making the signal ambiguous for the $77B media giant.
NMI Holdings CEO Adam Pollitzer filed a $7.7M sale on September 4. The mortgage insurance firm trades at a $3.2B market cap. CEO sales of this size draw attention, though they can reflect portfolio diversification.
Globally, the most notable institutional move came from Li Ning's parent, Viva China Holdings. It bought $67M worth of Li Ning shares on August 27, filed September 2. Founder-linked buying at that scale in a beaten-down Chinese sportswear stock is worth watching.
The market context is tricky. Nasdaq fell over 1% today as Treasury yields rose, and the Fear & Greed Index sits firmly in "Fear" territory. Executives buying into that environment — like the Cybin directors — carry more weight than usual.
Note: This is not financial advice. Insider trade significance should be judged in the context of each company's full picture.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
